BeiGene heads for profit milestone after hemorrhaging cash
累亏近600亿后，百济神州将实现经营利润

With a blockbuster drug under its belt and another product approved for U.S. sale, the biopharma firm says it is on track to post an annual operating profit this year.
虽然百济神州此前对于何时盈利这一问题始终含糊其辞，但是从业务发展趋势来看，2025年的财务表现值得期待。